Autoprobiotics as an Approach for Restoration of Personalised Microbiota

Abstract

Human microbiota is a complex consortium of microorganisms involved in the proper functioning of almost every system of the organism. Majority of the human diseases are associated with the development of intestinal dysbiosis. Dysbiotic condition or dysbiosis is a key pathogenic condition causing many severe infectious or non-infectious diseases. Rapid return to the original microbiota in many cases leads to the fast recovery from the disease. However, the optimal way of the treatment of dysbiosis is still under the discussion. Recently we have developed a method of autoprobiotics based on using isolated indigenous bacteria for improving of microbiota condition. The method based on feeding the patients with bacterial products grown from their personal, genetically characterised strains have been successfully tested in clinic on patients with IBS or chronic pneumonia. In present study we tried to evaluate technology employing autoprobiotic bacteria belonging to different species employing the rat model of antibiotic induced dysbiosis. Six experimental groups of animals after taking antibiotics were treated with different variants of autoprobiotics (lactobacillus, bifidobacteria, enterococcus, their mixture, fecal microbiota, or anaerobically grown complex of indigenous microbiota) prepared for each of them before the development of dysbiosis. Judging by the multiple parameters including metagenomics analysis of microbiota, immune status and microbiota content of the animals with dysbiosis relatively to control group, the most pronounced positive changes were provided by autoprobiotics based on enterococci, bifidobacteria or the consortium of indigenous bacteria grown under anaerobic conditions. These groups of autoprobiotics were delivering the most effective restoration of the original microbiota content and significant anti-inflammatory reaction of the immune system.

Detection of meningococcus, pneumococcus, Haemophilus influenzae, and group A streptococcus DNA in pediatric adenoid bioptats

“…Восстановление состава микробиоты носоглотки с помощью пробиотиков, то есть резидентных бактерий, обитающих на слизистых оболочках человека в норме, позволит проводить элиминацию патобионтов «экологически щадящим» способом [16,17]. Повысить терапевтическую эффективность пробиотиков возможно, к примеру, с помощью выращивания их в виде биопленок [30], а также -при использовании аутопробиотиков [28]. Такие подходы планируется применить в наших дальнейших исследованиях по санации носителей патобионтов, обитающих на слизистой оболочке носоглотки.…”

Untitled

“…The latter were detected earlier in a bacteriological study and by quantitative PCR. 18,46 Against the background of administration of AC, dysbiosis associated with excessive representation of opportunistic bacteria was associated only with genus Klebsiella, which representation was fewer than in the C1 group. A feature of metabolic changes in A group compared to healthy rats was an increase of AP activity in the distal parts of gastrointestinal tract, which could be associated with an increase of this enzyme producers relative abundancе.…”

“…Changes in the gut microbiota content were investigated by performing 16S rRNA gene-based metagenome analysis using a previously described approach. 18…”

“…[4][5][6][7][8][9][10][11][12][13] Because of the lack of biocompatibility between the host organism and its microbiota to the administered probiotics they are eliminated rapidly from the organism, and longer treatment periods are needed to achieve lasting results. [1][2][3][4][5][6][7][8][9][10][11][12][13][14] The use of beneficial indigenous bacteria (autoprobiotics) [15][16][17][18][19] or autologous fecal transplantation 18 has high potential for overcoming these problems. The efficacy of mono-strain autoprobiotics has been proven in an intestinal dysbiosis experimental model 14,18,20 in treating of irritable bowel syndrome, Parkinson's disease and when used with antibiotic treatments of pneumonia.…”

“…[1][2][3][4][5][6][7][8][9][10][11][12][13][14] The use of beneficial indigenous bacteria (autoprobiotics) [15][16][17][18][19] or autologous fecal transplantation 18 has high potential for overcoming these problems. The efficacy of mono-strain autoprobiotics has been proven in an intestinal dysbiosis experimental model 14,18,20 in treating of irritable bowel syndrome, Parkinson's disease and when used with antibiotic treatments of pneumonia. 1,4,16 However, the introduction of single components of intestinal microbiota cannot recreate the complete microbiota, characterized by a high biodiversity and the presence of its obligate representatives.…”